コネチカット州における乳がんの臨床試験
コネチカット州内の拠点で、乳がんに関する47件の研究が参加者を募集しています。
コネチカット州内の都市
- New Haven38件の研究
- East Norwalk35件の研究
- Bridgeport21件の研究
- Stamford9件の研究
- Hartford9件の研究
- Waterbury6件の研究
- Norwalk5件の研究
- New London4件の研究
- North Stamford4件の研究
公式研究テキスト（英語）
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Yale-New Haven Hospital-Yale Cancer Center, New Haven
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/05更新 · NCT06982521A Study of PHST001 in Advanced Solid Tumors
- Yale Cancer Center, New Haven
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/05更新 · NCT06840886The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Yale Cancer Center, New Haven
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Yale Cancer Center, New Haven
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06172478A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
- Yale University School of Medicine - Yale Cancer Center, New Haven
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07701941Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Yale University School of Medicine, New Haven
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT06324357A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
- Yale Cancer Center, New Haven
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07578571Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
- Yale University - Yale University School of Medicine, New Haven
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07360314An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
- Yale Cancer Center, New Haven
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07222267Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, New Haven
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05867251A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Yale Cancer Center ( Site 0060), New Haven
- Stamford Hospital ( Site 0049), Stamford
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06312176A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, New Haven
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06103864The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- Smilow Cancer Hospital Care Center - Derby, Derby
- Smilow Cancer Hospital Care Center - Fairfield, Fairfield
- Smilow Cancer Hospital at Glastonbury, Glastonbury
- 他10件
被験者募集中第3相
60歳以上 · 全性別 · 2026/09/25更新 · NCT06377852A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
- Kivu Trial Site, New Have
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/24更新 · NCT07229313Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Hartford Healthcare Institute, Hartford
- Yale Cancer Center, New Haven
被験者募集中
18歳以上 · 全性別 · 2026/09/23更新 · NCT07214532Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, New Haven
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/23更新 · NCT07085767A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
- Yale University School Of Medicine, New Haven
被験者募集中第1相
18歳以上 · 女性 · 2026/09/21更新 · NCT07524855Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
- Norwalk Hospital, Norwalk
被験者募集中第2相
45歳以上 · 女性 · 2026/09/21更新 · NCT04084730Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
- Yale Cancer Center Clinical Trials Office, New Haven
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/18更新 · NCT07340541A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Yale New Haven Hospital- Yale Cancer Center, New Haven
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/15更新 · NCT06492616Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- Yale Cancer Center, New Haven
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/04更新 · NCT05315700Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Smilow Cancer Hospital at Yale New Haven, New Haven
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/02更新 · NCT06072612Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Hartford HealthCare - Avon, Avon
- Hartford HealthCare - Saint Vincent's Medical Center, Bridgeport
- Danbury Hospital, Danbury
- 他19件
被験者募集中第3相
18歳〜60歳 · 女性 · 2026/09/02更新 · NCT05879926A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Yale Cancer Center, New Haven
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/28更新 · NCT07029399TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
- Yale University Cancer Center, New Haven
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/26更新 · NCT06533826ATEMPT 2.0: Adjuvant T-DM1 vs TH
- Smilow Cancer Hospital Care center at Derby, Derby
- Smilow Cancer Hospital Care center at Fairfield, Fairfield
- Smilow Cancer Hospital Care center at Glastonbury, Glastonbury
- 他11件
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/19更新 · NCT04893109Optimizing Surgical Decisions in Young Adults With Breast Cancer
- Yale Cancer Center, New Haven
被験者募集中
18歳〜44歳 · 女性 · 2026/08/19更新 · NCT06275126Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- Yale Cancer Center - Smilow Cancer Hospital, New Haven
被験者募集中第3相
18歳〜100歳 · 全性別 · 2026/08/06更新 · NCT05232916E-Mindfulness Approaches for Living After Breast Cancer
- Stamford Hospital/Bennett Cancer Center, Stamford
被験者募集中第3相
18歳〜50歳 · 全性別 · 2026/08/04更新 · NCT06748222A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Norwalk Hospital, Norwalk
被験者募集中第2相
8歳以上 · 全性別 · 2026/07/27更新 · NCT05503797Pre-Operative Window of ET to Inform RT Decisions (POWER II)
- Yale University, New Haven
被験者募集中第3相
65歳以上 · 女性 · 2026/06/30更新 · NCT06507618Integrated Cancer Repository for Cancer Research
- Hartford HealthCare Cancer Institute at Manchester Medical Hospital, Manchester
被験者募集中観察研究健康なボランティア歓迎
19歳〜110歳 · 全性別 · 2026/06/29更新 · NCT02012699Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Yale University, Yale Cancer Center, New Haven
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/23更新 · NCT06993844Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy
- Yale Cancer Center Smilow Cancer Hospital, New Haven
被験者募集中第1相
18歳以上 · 女性 · 2026/05/22更新 · NCT05989347Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
- Yale Cancer Center, New Haven
被験者募集中観察研究
18歳〜80歳 · 女性 · 2026/05/22更新 · NCT06551220I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Yale Cancer Center, New Haven
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/06更新 · NCT01042379A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Smilow Cancer Hospital - Derby, Derby
- Smilow Cancer Hospital - Fairfield, Fairfield
- Smilow Cancer Hospital - Glastonbury, Glastonbury
- 他7件
被験者募集中第3相
18歳以上 · 全性別 · 2026/05/06更新 · NCT07062965Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
- Stamford Hospital, Stamford
被験者募集中第2相
18歳以上 · 全性別 · 2026/04/29更新 · NCT04468061De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- Smilow Cancer Hospital-Derby Care Center, Derby
- Smilow Cancer Hospital Care Center-Fairfield, Fairfield
- Smilow Cancer Hospital Care Center at Glastonbury, Glastonbury
- 他13件
被験者募集中第3相
50歳〜70歳 · 全性別 · 2026/04/23更新 · NCT04852887A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- Yale University, Yale Cancer Center, New Haven
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/03/27更新 · NCT06395519ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。